Featured Content
Global breast cancer incidence is projected to reach more than 3.5 million cases and 1.37 million deaths by 2050, up…
Most Read
The Latest
Houston Methodist has tapped Daniela Matei, MD, as director of the Dr. Mary and Ron Neal Cancer Center. Dr. Matei will step into the role in April, according to a Feb. 27 news release from Houston Methodist. She currently serves…
BeOne Corporate Video
BeOne Medicines is a global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of novel therapeutics through its internal capabilities and…
Baton Rouge, La.-based Our Lady of the Lake Cancer Institute — part of FMOL Health — has become the first in Louisiana to administer CAR-T therapy in an outpatient setting. The cancer center began offering inpatient CAR-T therapy in May…
As associate vice president of oncology services at Phoenix-based Banner Health, Cory Jones oversees oncology services tied to the Banner MD Anderson Cancer Center program, which spans 10 sites across Arizona and Colorado. Banner is one of the largest nonprofit…
From NCI-designated cancer center directors and to endowed chairs, here are 11 health systems seeking leaders for oncology services:
Far Rockaway, N.Y.-based Episcopal Health Services has opened a cancer center within the system’s Walsh Ambulatory Pavilion. The EHS Cancer Center will provide medical and radiation oncology care, while surgical oncology services will remain at St. John’s Episcopal Hospital, located…
Of the $19.297 billion the National Institutes of Health awarded to 145 medical schools in fiscal 2025, about 3.43% was given to radiation or diagnostic oncology departments, according to data published by the Blue Ridge Institute for Medical Research. Philadelphia-based…
Seattle-based Fred Hutch Cancer Center has named Holly Harris, PhD, the inaugural Bus Family Endowed Chair. The endowed chair will support research in prevention, early detection and precision oncology related to uterine, ovarian and breast cancers, according to a Feb.…
The FDA has placed a partial clinical hold on a cancer drug trial following four safety events, including one death, according to a Feb. 25 announcement from MacroGenics. The partial hold pauses enrollment for MacroGenics’ phase 2 study on lorigerlimab, an experimental…
Pfizer received full FDA approval for its Braftovi (encorafenib) combination regimen as a first-line treatment for adult patients with BRAF V600E-mutant metastatic colorectal cancer. The approval covers Braftovi in combination with cetuximab and fluorouracil-based chemotherapy, including mFOLFOX6 and FOLFIRI, according…
